TrialFrontiers in immunology2022

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.

Andreas Reiter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.